Home Sectors Healthcare Present Trend: Meridian Bioscience (NASDAQ: VIVO)

Present Trend: Meridian Bioscience (NASDAQ: VIVO)

29
0
SHARE

Meridian Bioscience trades as part of the medical diagnostics and research industry and is part of the healthcare sector. The company CEO is Jack P. Kenny. Meridian Bioscience Inc is an integrated life science company. It is engaged in development, manufacture, sale and distribution of diagnostic test kits for certain gastrointestinal, viral, respiratory and parasitic infectious diseases.

Previous Intraday Trading Performance:

The VIVO stock showed a previous change of 0.37% with an open at 16.41 and a close of 16.49. It reached an intraday high of 16.51 and a low of 16.27.

SeekingAlpha:  Meridian Bioscience, Inc. (VIVO) CEO Jack Kenny on Q1 2019 Results – Earnings Call Transcript

Liquidity:

The stock has a market cap of $700.6m with 42.5m shares outstanding, of which the float is 40.8m shares. Trading volume reached 189,382 shares compared to its average volume of 299,410 shares. Based on the current average volume and close price, the trading liquidity is bad, highly speculative and an investor may want to avoid this stock.

Historical Trading Performance:

Over the last five trading days, Meridian Bioscience shares returned -3.17% and in the past 30 trading days it returned -2.08%. Over three months, it changed -9.45%. In one year it has changed 14.60% and within that year its 52-week high was 19.84 and its 52-week low was 13.75. VIVO stock is 19.93% above its 52 Week Low.

Our calculations show a 200 day moving average of 16.00 and a 50 day moving average of 16.53. Currently VIVO stock is trading 3.06% above its 200 day moving average and may be a good opportunity to buy.

SeekingAlpha:  Meridian Bioscience Inc. 2019 Q1 – Results – Earnings Call Slides

Earnings:

The last annual fiscal EPS for the company was reported at 0.56 that ended on 30th of September 2018, which according to the previous close, that is a PE of 29.45. Based on 3 analyst estimates, the consensus EPS for the next quarter is 0.16. The TTM EPS is 0.74, which comes to a TTM PE of 22.28. Historically, the PE high was 32.90 and the PE low was 14.10. If the stock reached its PE low, that would represent a price of 10.44, which is a decrease of -36.71%.

The following are the last four quarter reported earnings per share:
12-31-2018:  0.20
09-30-2018:  0.20
06-30-2018:  0.18
03-31-2018:  0.21

The dividend per share is currently 0.50, which is a dividend yield of 3.03%.

Base on our calculations, the intrinsic value per share is 16.76, which means it is possibly undervalued and has a margin of safety of 1.60%

Indicators to Watch:

Based on the latest filings, there is 3.90% of insider ownership and 132.00% of institutional ownership. Short-interest is 0, which is 0.00% of shares outstanding. The short-interest ratio or days-to-cover ratio is 0.00.

The current calculated beta is 0.49

SeekingAlpha:  Meridian Bioscience fiscal Q1 beats EPS consensus

Fundamental Indicators:

Based on last reported financials, the company’s return on equity is 14.60%, return on assets is 10.22%, profit margin is 12.06%, price-to-sales is 3.28 and price-to-book is 4.05.

Company Scores:

All scores are out of six:
 2  :Valuation Score
 2  :Past Performance Score
 5  :Financial Strength Score
 1  :Future Growth Score
 4  :Dividend Score
 2  :Overall Score

SHARE
John Jones
Worked for several Wall Street firms: Salomon Smith Barney, UBS, and Charles Schwab. Has developed skills and gained extensive experience over the years that is used today to uncover winning penny stocks.Also was an attorney for small businesses in Scottsdale, Arizona. That experience and understanding of law provides a unique perspective and edge in discovering quality companies in various industries.